Loading…
Please register to continue your trial period!
meRfi Microbiome provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.
Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.
Start your free trial and transform your understanding of the gut microbiota today!
ADC-001 is the lead drug candidate developed by NovoBiome, a French drug discovery company specializing in therapies that target the Microbiota-Gut-Liver-Axis (GLA). ADC-001 is a Next-Generation Probiotics (NGPs) specifically designed for the treatment of liver diseases.
ADC-001 consists of an anti-inflammatory bacterium from the class Coriobacteriia / Coriobacteria, specifically Adlercreutzia equolifaciens, an equol-producing bacterium isolated from human feces. It is in preclinical …